Journal
ANNALS OF SURGICAL ONCOLOGY
Volume 28, Issue 3, Pages 1320-1325Publisher
SPRINGER
DOI: 10.1245/s10434-020-09382-w
Keywords
-
Ask authors/readers for more resources
This study found that Oncotype DX(R) RS can serve as an independent predictor for axillary pathologic complete response in ER +/HER2 - breast cancer patients receiving neoadjuvant chemotherapy. A greater proportion of patients with a high RS achieved axillary pCR, supporting the use of Oncotype DX(R) as a tool to improve clinical decision making in axillary management.
Introduction Oncotype DX(R) recurrence score (RS) is well-recognized for guiding decision making in adjuvant chemotherapy; however, the predictive capability of this genomic assay in determining axillary response to neoadjuvant chemotherapy (NCT) has not been established. Methods Using the National Cancer Data Base (NCDB), we identified patients diagnosed with T1-T2, clinically N1/N2, estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER +/HER2 -) invasive ductal carcinoma of the breast between 2010 and 2015. Patients with an Oncotype DX(R) RS who received NCT were included. RS was defined as low (< 18), intermediate (18-30), or high (> 30). Unadjusted and adjusted analyses were performed to determine the association between axillary pathologic complete response (pCR) and RS. Results This study included a total of 158 women. RS was low in 56 (35.4%) patients, intermediate in 62 (39.2%) patients, and high in 40 (25.3%) patients. The majority of patients presented with clinical N1 disease (89.2%). Axillary pCR was achieved in 23 (14.6%) patients. When stratifying patients with axillary pCR by RS, 11 (47.8%) patients had a high RS, 6 (26.1%) patients had an intermediate RS, and 6 (26.1%) patients had a low RS. Comparing cohorts by RS, 27.5% of patients with high RS tumors had an axillary pCR, compared with only 9.7% in the intermediate RS group, and 10.7% in the low RS group (p = 0.0268). Conclusion Our findings demonstrate that Oncotype DX(R) RS is an independent predictor of axillary pCR in patients with ER +/HER2 - breast cancers receiving NCT. A greater proportion of patients with a high RS achieved axillary pCR. These results support Oncotype DX(R) as a tool to improve clinical decision making in axillary management.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available